| Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance SY Ku, S Rosario, Y Wang, P Mu, M Seshadri, ZW Goodrich, ... Science 355 (6320), 78-83, 2017 | 1027 | 2017 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 189 | 2021 |
| High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program DP Labbé, G Zadra, M Yang, JM Reyes, CY Lin, S Cacciatore, EM Ebot, ... Nature communications 10 (1), 4358, 2019 | 164 | 2019 |
| The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis S Hardy, N Uetani, N Wong, E Kostantin, DP Labbé, LR Bégin, ... Oncogene 34 (8), 986-995, 2015 | 138 | 2015 |
| The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration D Labbé, M Provençal, S Lamy, D Boivin, D Gingras, R Béliveau The Journal of nutrition 139 (4), 646-652, 2009 | 133 | 2009 |
| ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer G Deblois, HW Smith, IS Tam, SP Gravel, M Caron, P Savage, DP Labbé, ... Nature communications 7, 12156, 2016 | 126 | 2016 |
| TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup DP Labbé, CJ Sweeney, M Brown, P Galbo, S Rosario, KM Wadosky, ... Clinical Cancer Research 23 (22), 7072-7083, 2017 | 121 | 2017 |
| MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets X Qiu, N Boufaied, T Hallal, A Feit, A de Polo, AM Luoma, W Alahmadi, ... Nature Communications 13 (1), 1-17, 2022 | 120 | 2022 |
| Effect of brewing temperature and duration on green tea catechin solubilization: Basis for production of EGC and EGCG-enriched fractions D Labbé, A Tremblay, L Bazinet Separation and Purification Technology 49 (1), 1-9, 2006 | 118 | 2006 |
| The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases D Boivin, D Labbé, N Fontaine, S Lamy, É Beaulieu, D Gingras, ... Biochemistry 48 (18), 3998-4007, 2009 | 112 | 2009 |
| PTP1B is an androgen receptor–regulated phosphatase that promotes the progression of prostate cancer L Lessard, DP Labbé, G Deblois, LR Bégin, S Hardy, AM Mes-Masson, ... Cancer research 72 (6), 1529-1537, 2012 | 91 | 2012 |
| Production of green tea EGC-and EGCG-enriched fractions by a two-step extraction procedure L Bazinet, D Labbé, A Tremblay Separation and purification technology 56 (1), 53-56, 2007 | 83 | 2007 |
| Transcriptional Regulation in Prostate Cancer DP Labbé, M Brown Cold Spring Harbor perspectives in medicine 8 (11), a030437, 2018 | 81 | 2018 |
| Protein tyrosine phosphatases in cancer: friends and foes! DP Labbé, S Hardy, ML Tremblay Progress in molecular biology and translational science 106, 253-306, 2012 | 80 | 2012 |
| Electromigration feasibility of green tea catechins D Labbé, M Araya-Farias, A Tremblay, L Bazinet Journal of membrane science 254 (1-2), 101-109, 2005 | 76 | 2005 |
| Role of diet in prostate cancer: the epigenetic link DP Labbé, G Zadra, EM Ebot, LA Mucci, PW Kantoff, M Loda, M Brown Oncogene 34 (36), 4683-4691, 2014 | 66 | 2014 |
| Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling S Lamy, É Beaulieu, D Labbé, V Bédard, A Moghrabi, S Barrette, ... Carcinogenesis 29 (5), 1033-1041, 2008 | 65 | 2008 |
| Green Tea for Ovarian Cancer Prevention and Treatment: A Systematic Review of the in Vitro, in Vivo and Epidemiological Studies D Trudel, DP Labbé, I Bairati, V Fradet, L Bazinet, B Têtu Gynecologic Oncology 126, 491-498, 2012 | 64 | 2012 |
| Catechin stability of EGC-and EGCG-enriched tea drinks produced by a two-step extraction procedure D Labbé, B Têtu, D Trudel, L Bazinet Food Chemistry 111 (1), 139-143, 2008 | 64 | 2008 |
| A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer D Trudel, DP Labbé, M Araya-Farias, A Doyen, L Bazinet, T Duchesne, ... Gynecologic oncology 131 (2), 357-361, 2013 | 58 | 2013 |
Myles BrownEmil Frei III Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical SchoolVerified email at dfci.harvard.edu
